About this trial
Coronary artery disease (CAD) is a heart disease caused by the buildup of plaque inside the coronary arteries that restricts blood flow to the heart which leads to heart attack. If it involve more than one artery it will be more critical so the preferred treatment will be coronary artery bypass graft. Respiratory failure after Coronary Artery Bypass Grafting (CABG) is a serious complication with multifactorial causes i.e. pneumonia and atelectasis in inpatients.
Postoperative pulmonary complications will be diagnosed using the Melbourne Group Scale (MGS), applied daily from postoperative day 1 to day 7. A score of ≥4 positive criteria will be used to identify PPCs. The scale's criteria will include chest radiograph findings, oxygen saturation, sputum characteristics, inflammatory markers, and ventilation data, physician diagnosis of pneumonia, readmission to ICU for respiratory reasons, prolong ventilation\> 24 hours, unplanned use of non-invasive ventilation.
Eligibility criteria
Qualifiers
Male and female of >45 years diagnosed with CAD and are undergone Coronary Artery Bypass Graft with stable circulation.
Stable vitals.
With normal cognition and being able to cooperate with the CR training.
Agreed to participate in the trial and signed the consent for .
Disqualifiers
Pregnant
Undergoing aortic surgery or equivalent surgery within 6 months
History of cardiogenic shock or sudden cardiac arrest and severe hypertension
Having complications with persistent ischemia, hemodynamic impairment, or at risk of arterial occlusion with massive myocardial infarction
Trial design
Treatments tested in this trial
- IMT Threshold device